Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

by Business Wire • 2022/06/10 • 0 Comments

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced its presentation of a post-hoc analysis from the Zimura GATHER1 clinical trial at the Macula Society Meeting in Berlin, Germany.

← Insights on the Face Mask Detection Global Market to 2027 – Increasing Innovations in Face Detection, AI and Image Processing Technologies Present Opportunities – ResearchAndMarkets.com

Organizational changes to support development of retina programs at Ocular Therapeutix →

Post navigation